Anti-vascular aging composition based on 1, 2, 3, 4, 6-pentagalloylglucose and application thereof

Abstract

The invention provides an anti-vascular aging composition based on 1, 2, 3, 4, 6-pentagalloylglucose and application thereof, relates to the technical field of biology, and provides an anti-vascular aging composition based on 1, 2, 3, 4, 6-pentagalloylglucose for preventing or improving vascular aging. 1, 2, 3, 4, 6-pentagalloylglucose can effectively inhibit vascular endothelial cell aging and vascular aging, and the composition has the characteristics of high efficiency, safety, good stability and the like.

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to an anti-vascular aging composition based on 1,2,3,4,6-pentagalloyl glucose and its application. Background Art

[0002] With the aggravation of population aging, the incidence of vascular aging-related diseases has been increasing year by year, which has become an important problem seriously affecting human health and quality of life. Vascular aging is mainly manifested as the decline of vascular endothelial cell function, the change of vascular wall structure and the abnormality of vascular vasomotor function. These changes are the key factors in the occurrence and development of cardiovascular diseases.

[0003] At present, the prevention and treatment methods for vascular aging mainly include drug treatment, lifestyle intervention, etc. However, the existing treatment methods still have certain limitations, such as unsatisfactory curative effect, large side effects and other problems, and there is an urgent need to explore new strategies.

[0004] In recent years, natural plant extracts have attracted much attention in the field of anti-vascular aging due to their multi-target and low-toxicity characteristics. Among them, gallic acid esters, as a common plant active ingredient, have been found to have a variety of biological activities. Research shows that 1,2,3,4,6-pentagalloyl glucose (PGG), as a gallic acid ester compound, in addition to having anti-inflammatory and antioxidant properties, also promotes the relaxation of vascular smooth muscle and inhibits vascular inflammation by activating the endothelial-dependent NO / cGMP signal transduction pathway. However, the specific role and mechanism of PGG in anti-vascular endothelial cell aging and vascular aging have not been fully studied.

[0005] In view of this, the present invention is specifically proposed. Summary of the Invention

[0006] One object of the present invention is to provide an application of 1,2,3,4,6-pentagalloyl glucose in the preparation of an anti-vascular aging product, so as to solve at least one of the technical problems existing in the prior art.

[0007] Another object of the present invention is to provide an anti-vascular aging composition based on 1,2,3,4,6-pentagalloyl glucose. The anti-vascular aging composition is used for preventing or improving vascular aging, and has the characteristics of high efficiency, safety, good stability, etc.

[0008] A third object of the present invention is to provide an application of the anti-vascular aging composition in the preparation of food or health products.

[0009] A fourth object of the present invention is to provide an application of the anti-vascular aging composition in the preparation of anti-vascular aging drugs.

[0010] To achieve the above object of the present invention, the following technical solutions are specifically adopted:

[0011] In a first aspect, the present invention provides an application of 1,2,3,4,6-pentagalloylglucose in the preparation of a product for anti-vascular aging.

[0012] Furthermore, the effective substance concentration of 1,2,3,4,6-pentagalloylglucose for improving the senescence of vascular endothelial cells is 0.5 - 20 μM.

[0013] Furthermore, the effective substance concentration of 1,2,3,4,6-pentagalloylglucose for improving the senescence of vascular endothelial cells is 10 μM.

[0014] Furthermore, 1,2,3,4,6-pentagalloylglucose is used to improve the senescence of vascular endothelial cells, and the vascular endothelial cells include primary human umbilical vein endothelial cells.

[0015] In a second aspect, the present invention provides an anti-vascular aging composition based on 1,2,3,4,6-pentagalloylglucose, and its components include 1,2,3,4,6-pentagalloylglucose and optional excipients.

[0016] Furthermore, the anti-vascular aging composition includes the following components by weight percentage:

[0017] 0.01% - 0.5% of 1,2,3,4,6-pentagalloylglucose and the balance of excipients.

[0018] Furthermore, the excipients include at least one of an antioxidant and an anti-inflammatory agent;

[0019] and / or, the antioxidant includes at least one of vitamin C and catechin;

[0020] and / or, the anti-inflammatory agent includes tea polyphenols.

[0021] In a third aspect, the present invention provides an application of the anti-vascular aging composition in the preparation of food or health products.

[0022] In a fourth aspect, the present invention provides an application of the anti-vascular aging composition in the preparation of anti-vascular aging drugs.

[0023] Compared with the prior art, the present invention has the following beneficial effects:

[0024] The anti-vascular aging composition based on 1,2,3,4,6-pentagalloylglucose (PGG) provided by the present invention, PGG is used to improve the replicative senescence of vascular endothelial cells and the pathological endothelial cell senescence induced by high glucose, oxidative stress, and 5-fluorouracil chemotherapy drugs, and its specific manifestations are as follows: the PGG can significantly reduce the expression of cell cycle inhibitors P16 and P21 in vascular endothelial cells; the PGG can significantly reduce the presence of galactosidase staining deposits in endothelial cells; the PGG anti-vascular aging composition is used to improve the vascular aging induced by the natural aging model. Its specific manifestations are as follows: the PGG composition can enhance the expression level of NO in the serum of aging mice; the PGG composition reduces the levels of senescence-related secretory factors interleukin-1β (IL-1β) and interleukin-6 (IL-6) in the serum of mice. This anti-vascular aging composition can be applied to the fields of food, health products, or drugs, which can not only effectively scavenge free radicals, reduce oxidative stress, but also improve vascular endothelial function and inhibit inflammatory reactions, thereby delaying the process of vascular aging. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] In order to more clearly illustrate the specific embodiments of the present invention or the technical solutions in the prior art, the following will briefly introduce the drawings required for the description of the specific embodiments or the prior art. Obviously, the drawings in the following description are some embodiments of the present invention. For those of ordinary skill in the art, without creative efforts, other drawings can also be obtained based on these drawings.

[0026] Figure 1 For the expression levels of P16 and P21 proteins after 1,2,3,4,6-pentagalloylglucose treatment of replicative senescent endothelial cells provided in Examples 1-4 of the present invention;

[0027] Figure 2 For the proliferation activity of senescent endothelial cells detected by CCK-8 after 1,2,3,4,6-pentagalloylglucose treatment of replicative senescence and pathological senescence provided in Examples 1-4 of the present invention;

[0028] Figure 3 For the accumulation level of β-galactosidase in senescent endothelial cells after 1,2,3,4,6-pentagalloylglucose treatment of replicative senescence and pathological senescence provided in Example 1 of the present invention;

[0029] Figure 4 For the secretion levels of IL-1β and IL-6 in the serum after the 1,2,3,4,6-pentagalloylglucose complex acts on aging mice provided in Examples 5-7 of the present invention;

[0030] Figure 5The secretion level of NO in the serum after the 1,2,3,4,6-pentagalloylglucose complex provided in Examples 5-7 of the present invention acts on aging mice. Detailed implementation manners

[0031] Unless otherwise defined herein, scientific and technical terms used in conjunction with the present invention shall have the meanings commonly understood by those of ordinary skill in the art. The meanings and scopes of the terms should be clear. However, in any case of potential ambiguity, the definitions provided herein shall prevail over any dictionary or extrinsic definition. In this application, unless otherwise specified, the use of "or" means "and / or". In addition, the use of the term "comprising" and other forms is non-restrictive.

[0032] Generally, the nomenclature and techniques used in conjunction with cell and tissue culture, molecular biology, immunology, microbiology, genetics, and protein and nucleic acid chemistry and hybridization described herein are those well known and commonly used in the art. Unless otherwise specified, the methods and techniques of the present invention are generally carried out according to conventional methods well known in the art and as described in various general and more specific references, which are cited and discussed throughout this specification. Enzymatic reactions and purification techniques are carried out according to the manufacturer's instructions, as commonly practiced in the art or as described herein. The nomenclature, as well as the laboratory procedures and techniques used in conjunction with analytical chemistry, synthetic organic chemistry, and medical and pharmaceutical chemistry described herein, are those well known and commonly used in the art.

[0033] Next, the technical solutions of the present invention will be clearly and completely described in conjunction with the embodiments. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. All other embodiments obtained by those of ordinary skill in the art based on the embodiments of the present invention without creative efforts shall fall within the protection scope of the present invention.

[0034] The first aspect of the present invention provides an application of 1,2,3,4,6-pentagalloylglucose (PGG) in the preparation of products for anti-vascular aging.

[0035] PGG is used to improve the replicative senescence of vascular endothelial cells and the pathological endothelial cell senescence induced by high glucose, oxidative stress, and the chemotherapeutic drug 5-fluorouracil. Specifically, the PGG can significantly reduce the expression of the cell cycle inhibitory factors P16 and P21 in vascular endothelial cells; the PGG can significantly reduce the presence of galactosidase staining deposits in endothelial cells.

[0036] In some preferred implementation manners, the effective substance concentration of 1,2,3,4,6-pentagalloylglucose for improving the senescence of vascular endothelial cells is 0.5-20 μM, more preferably 10 μM.

[0037] In some preferred embodiments, 1,2,3,4,6-pentagalloylglucose is used to improve the senescence of vascular endothelial cells, and the vascular endothelial cells include primary human umbilical vein endothelial cells (HUVEC).

[0038] In the present invention, PGG is used to improve the replicative senescence of vascular endothelial cells and the pathological senescence of endothelial cells induced by high glucose, oxidative stress, and 5-fluorouracil chemotherapy drugs. Specifically, PGG can significantly reduce the expression of cell cycle inhibitors P16 and P21 in vascular endothelial cells; PGG can significantly reduce the presence of galactosidase staining deposits in endothelial cells.

[0039] The second aspect of the present invention provides an anti-vascular aging composition based on 1,2,3,4,6-pentagalloylglucose, and its components include 1,2,3,4,6-pentagalloylglucose and optional excipients.

[0040] The anti-vascular aging composition in the present invention uses PGG as the main active ingredient, as well as excipients acceptable in food and health products.

[0041] The anti-vascular aging composition based on 1,2,3,4,6-pentagalloylglucose (PGG composition) provided by the present invention is used to improve the vascular aging induced by natural aging models. Specifically, the PGG composition can enhance the NO expression level in the serum of senescent mice; the PGG composition reduces the levels of senescence-related secretory factors interleukin-1β (IL-1β) and interleukin-6 (IL-6) in the serum of mice.

[0042] Preferably, the excipient can also be an excipient acceptable in drugs.

[0043] In some preferred embodiments, the anti-vascular aging composition comprises the following components by weight percentage:

[0044] 0.01%-0.5% 1,2,3,4,6-pentagalloylglucose and the balance of excipients.

[0045] Based on the total weight of the anti-vascular aging composition being 100%, the addition amount of 1,2,3,4,6-pentagalloylglucose is 0.01%-0.5%, for example, it can be 0.01%, 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, etc., and the balance is excipients. In the anti-vascular aging composition, the weight percentage of PGG is 0.01% to 0.5%.

[0046] In some preferred embodiments, in addition to including excipients acceptable in food, health products, and drugs, the excipient also includes one or more other active ingredients selected from at least one of antioxidants and anti-inflammatory agents;

[0047] And / or, the oxidant includes at least one of vitamin C and catechin;

[0048] And / or, the anti-inflammatory agent includes tea polyphenols.

[0049] The third aspect of the present invention provides an application of an anti-vascular aging composition in the preparation of foods or health products.

[0050] The fourth aspect of the present invention provides an application of an anti-vascular aging composition in the preparation of anti-vascular aging drugs.

[0051] Based on the multiple biological activities of PGG, the present invention proposes a complex with PGG as the core. By synergistically acting with other natural active ingredients, its anti-vascular aging effect is further enhanced. This complex can be applied to the fields of foods, health products or drugs, and can not only effectively scavenge free radicals and reduce oxidative stress, but also improve vascular endothelial function and inhibit inflammatory responses, thereby delaying the process of vascular aging.

[0052] Compared with the prior art, the present invention has the following advantages and beneficial effects:

[0053] In the present invention, natural passage is used to simulate the replicative senescence of vascular endothelial cells, and glucose, hydrogen peroxide, and 5-fluorouracil are used to simulate the pathological senescence of vascular endothelial cells induced by high glucose, oxidative stress, and chemotherapeutic drugs, respectively. Through the treatment with PGG, it is found that it can significantly improve the natural senescence and pathological senescence of vascular endothelial cells. Specifically, PGG significantly reduces the expression of cell cycle inhibitors P16 and P21 in vascular endothelial cells; at the same time, it also significantly reduces the presence of galactosidase staining deposits in endothelial cells.

[0054] The present invention uses 15-month-old wild-type C57B6J mice to establish a natural aging vascular model. During the experiment, by intraperitoneal injection of the PGG complex, it is found that it can improve the vascular aging induced by the natural aging model. Specifically, PGG can significantly reduce the expression levels of senescence-related secretory factors interleukin-1β and interleukin-6 in the serum of mice. To further detect the effectiveness of PGG in delaying vascular aging, the secretion level of NO in the serum of mice is analyzed, and it is found that PGG can significantly enhance the secretion level of NO in the serum of mice.

[0055] The present invention first focuses on the anti-aging function of PGG on the vascular system and verifies it using reasonable and scientific experimental methods.

[0056] The present invention will be further described below by examples. Unless otherwise specified, the materials in the examples are prepared according to existing methods or directly purchased from the market.

[0057] The CAS number of 1,2,3,4,6-pentagalloylglucose is 14937-32-7.

[0058] Example 1

[0059] The preparation process of the working solution of 1,2,3,4,6-pentagalloylglucose is as follows:

[0060] Accurately weigh 23.517 mg of 1,2,3,4,6-pentagalloylglucose powder using an analytical balance and place it in a 15 mL sterile centrifuge tube. In a laminar flow hood, use a micropipette to add 5 mL of autoclaved water to the centrifuge tube, and repeatedly pipette with the pipette tip until the powder is completely dissolved in the autoclaved water, and the solution is clear without particles and impurities. After filtering and sterilizing with a 0.22 μm filter, a stock solution with a concentration of 5 mM is obtained, which is then aliquoted and stored in an ultra-low temperature freezer. When intervening with cells in vitro, take out the aliquoted 1,2,3,4,6-pentagalloylglucose stock solution from the ultra-low temperature freezer, melt it in a 37 °C water bath and then centrifuge at high speed, place it in a laminar flow hood, and the final concentration of the working solution for intervening with cells is 10 μM. The preparation process is as follows: According to the ratio of 1 mL of complete medium: 2 μL of 1,2,3,4,6-pentagalloylglucose stock solution, use a micropipette to add the stock solution to the complete medium, mix well with the pipette tip and then add it to the cell culture dish. After the operation, place the culture dish in a cell culture incubator for incubation.

[0061] Example 2

[0062] The difference in the preparation of the working solution of 1,2,3,4,6-pentagalloylglucose in Example 2 from that in Example 1 is that the final concentration of the working solution for intervening with cells is 1 μM, and the preparation process is as follows: According to the ratio of 1 mL of complete medium: 0.2 μL of 1,2,3,4,6-pentagalloylglucose stock solution, use a micropipette to add the stock solution to the complete medium, and the remaining steps are the same as those in Example 1.

[0063] Example 3

[0064] The difference in the preparation of the working solution of 1,2,3,4,6-pentagalloylglucose in Example 3 from that in Example 1 is that the final concentration of the working solution for intervening with cells is 20 μM, and the preparation process is as follows: According to the ratio of 1 mL of complete medium: 4 μL of 1,2,3,4,6-pentagalloylglucose stock solution, use a micropipette to add the stock solution to the complete medium, and the remaining steps are the same as those in Example 1.

[0065] Example 4

[0066] The difference in the preparation of the working solution of 1,2,3,4,6-pentagalloylglucose in Example 4 from that in Example 1 is as follows: the final concentration of the working solution for intervening cells is 0.5 μM, and the preparation process is as follows: according to the ratio of 1 mL of complete medium: 0.1 μL of the stock solution of 1,2,3,4,6-pentagalloylglucose, use a micropipette to add the stock solution to the complete medium, and the remaining steps are the same as those in Example 1.

[0067] Example 5

[0068] A solvent containing 1,2,3,4,6-pentagalloylglucose is prepared as follows:

[0069] Add 10 mg of 1,2,3,4,6-pentagalloylglucose (PGG) and 100 mg of cyclodextrin to about 8 mL of pure water, stir until completely dissolved; then add 10 mg of tea polyphenols and continue to stir until homogeneous; then add 50 mg of vitamin C and stir until completely dissolved; transfer the solution to a 10 mL volumetric flask, make up the volume to 10 mL with pure water, and shake gently. Finally, a homogeneous solution containing PGG (1 mg / mL), green tea extract (1 mg / mL), vitamin C (5 mg / mL) and cyclodextrin (10 mg / mL) is obtained.

[0070] Example 6

[0071] The difference in the preparation of the working solution of 1,2,3,4,6-pentagalloylglucose in Example 6 from that in Example 5 is as follows: accurately weigh 50 mg of 1,2,3,4,6-pentagalloylglucose, and the remaining steps are the same as those in Example 5. The concentration of 1,2,3,4,6-pentagalloylglucose in the final composition is 5 mg / mL.

[0072] Example 7

[0073] The difference in the preparation of the working solution of 1,2,3,4,6-pentagalloylglucose in Example 7 from that in Example 5 is as follows: accurately weigh 100 mg of 1,2,3,4,6-pentagalloylglucose, and the remaining steps are the same as those in Example 5. The concentration of 1,2,3,4,6-pentagalloylglucose in the final composition is 10 mg / mL.

[0074] Comparative Example 1

[0075] The difference in the preparation of the working solution in Comparative Example 1 from that in Example 1 is as follows: after filtering and sterilizing distilled water through a 0.22 μm filter, it is used as the control working solution in Examples 1-4, and the usage volume is the same as that of 1,2,3,4,6-pentagalloylglucose in Example 3.

[0076] Comparative Example 2

[0077] The difference in the solvent preparation between Comparative Example 2 and Example 5 is as follows: Sterile normal saline was used as the working solution for the control group in Examples 5 - 7, and the volume used was the same as that of the composition in Example 7.

[0078] The preparation process of the replicative senescent cells used in the following experimental examples and control examples is as follows:

[0079] Primary human umbilical vein endothelial cells were subcultured using ECM medium (37 °C, 5% CO2), and young endothelial cells were selected for the experiment (P3 - P5). Through normal subculture, endothelial cells with P > 15 were selected as replicative senescent cells.

[0080] Experimental Examples 1 - 4: Detection of P16 and P21 protein levels in senescent endothelial cells

[0081] Experimental Examples 1 - 4 were respectively tested using the working solutions prepared in Examples 1 - 4:

[0082] Primary human umbilical vein endothelial cells were subcultured using ECM medium (37 °C, 5% CO2), and young endothelial cells were selected for the experiment (P3 - P5). Through normal subculture, endothelial cells with P > 15 were selected as replicative senescent cells. In Experimental Examples 1 - 4, the cells were intervened with the 1,2,3,4,6 - pentagalloylglucose working solutions in Examples 1 - 4 and maintained for 24 h. After the induction ended, the protein levels of P16 and P21 were detected using Western blot.

[0083] Control Example 1

[0084] The working solution prepared in Comparative Example 1 was used for testing, and the testing method was the same as that in Experimental Example 1.

[0085] The experimental results are as Figure 1 shown. 1,2,3,4,6 - Pentagalloylglucose significantly reduced the protein levels of P16 and P21 in replicative senescent endothelial cells. P16 and P21 are considered to be marker proteins of senescence, which indicates that 1,2,3,4,6 - pentagalloylglucose significantly reduces the protein levels of P16 and P21 in senescent endothelial cells, and 1,2,3,4,6 - pentagalloylglucose can delay the senescence of endothelial cells.

[0086] Experimental Examples 5 - 8: Experiment on the effect of 1,2,3,4,6 - pentagalloylglucose on the proliferation of senescent endothelial cells Experimental Examples 5 - 8 were respectively tested using the working solutions prepared in Examples 1 - 4:

[0087] Young endothelial cells were stimulated and induced by adding glucose (30 mM), H2O2 (200 μM), and 5-fluorouracil (1 μM) to the culture medium respectively for 24 h to form senescent endothelial cells induced by high glucose, oxidative stress, and chemotherapeutic drugs. Together with replicative senescent endothelial cells, they were then intervened with the 1,2,3,4,6-pentagalloylglucose working solutions in Examples 1-4 for 48 h. Subsequently, the cell proliferation activity was detected by a CCK-8 kit. Among them, in Experimental Example 5, the replicative senescent endothelial cells were intervened with the 1,2,3,4,6-pentagalloylglucose working solutions in Examples 1-4; in Experimental Example 6, the high-glucose senescent endothelial cells were intervened with the 1,2,3,4,6-pentagalloylglucose working solutions in Examples 1-4; in Experimental Example 7, the oxidative stress senescent endothelial cells were intervened with the 1,2,3,4,6-pentagalloylglucose working solutions in Examples 1-4; in Experimental Example 8, the chemotherapeutic drug-induced senescent endothelial cells were intervened with the 1,2,3,4,6-pentagalloylglucose working solutions in Examples 1-4.

[0088] Control Example 2

[0089] The working solution prepared in Comparative Example 1 was used for testing, and the testing method was the same as that in Experimental Example 5.

[0090] The experimental results are as Figure 2 shown: 1,2,3,4,6-Pentagalloylglucose significantly enhanced the proliferation ability of replicative senescent ( Figure 2 A) and chemotherapeutic drug-induced senescent ( Figure 2 D) endothelial cells, and significantly inhibited the senescent endothelial cells damaged by oxidative stress ( Figure 2 C), but had no obvious effect on high-glucose-induced endothelial senescence ( Figure 2 B). The experimental results suggest that the anti-endothelial senescence effect of 1,2,3,4,6-pentagalloylglucose may exist in multiple ways of delaying senescence or killing senescent cells.

[0091] Experimental Examples 9-12: Detection of galactosidase staining deposits in senescent endothelial cells

[0092] Experimental Examples 9-12 were respectively tested with the working solutions prepared in Example 1:

[0093] Young endothelial cells were stimulated and induced by adding glucose (30 mM), H2O2 (200 μM), and 5-fluorouracil (1 μM) to the culture medium respectively for 24 h to form senescent endothelial cells induced by high glucose, oxidative stress, and chemotherapeutic drugs. Together with replicative senescent endothelial cells, they were then intervened with the 1,2,3,4,6-pentagalloylglucose working solution in Example 1 for 24 h. After the induction, they were stained with the galactosidase staining working solution and photographed. Scale bar, 200 μm. Among them, in Experimental Example 9, the replicative senescent endothelial cells were intervened with the 1,2,3,4,6-pentagalloylglucose working solution in Example 1; in Experimental Example 10, the high-glucose senescent endothelial cells were intervened with the 1,2,3,4,6-pentagalloylglucose working solution in Example 1; in Experimental Example 11, the oxidative stress senescent endothelial cells were intervened with the 1,2,3,4,6-pentagalloylglucose working solution in Example 1; in Experimental Example 12, the chemotherapeutic drug-induced senescent endothelial cells were intervened with the 1,2,3,4,6-pentagalloylglucose working solution in Example 1.

[0094] Control Example 3

[0095] The working solution prepared in Comparative Example 1 was used for testing, and the testing method was the same as that in Experimental Example 9.

[0096] The experimental results are as Figure 3 shown: 1,2,3,4,6-Pentagalloylglucose significantly reduced the accumulation of galactosidase staining deposits in replicative senescent ( Figure 3 A and B) and high-glucose ( Figure 3 A and C), oxidative stress ( Figure 3 A and D), and chemotherapeutic drug-induced ( Figure 3 A and E) senescent endothelial cells. The galactosidase staining method is a currently recognized senescence detection method, and the experimental results suggest that 1,2,3,4,6-pentagalloylglucose can delay the replicative senescence and pathological senescence of endothelial cells, which is consistent with the Figure 1 experimental results at the molecular level.

[0097] Experimental Examples 13 - 15: Testing the secretion levels of IL-1β and IL-6 in mouse serum

[0098] Experimental Examples 13 - 15 were respectively tested with the solutions prepared in Examples 5 - 7:

[0099] All the mice used in the experiment were 15-month-old aged mice, with 6-7 mice in each group. In Experimental Examples 13-15, the PGG composite solution in Examples 5-7 was intraperitoneally injected into the mice once every 4 days. After continuous administration for four weeks, blood was taken from the orbital cavity, serum was separated, and the secretion levels of IL-1β and IL-6 in the mouse serum were detected.

[0100] Control Example 4

[0101] The solution prepared in Comparative Example 2 was used for testing, and the testing method was the same as that in Experimental Example 13.

[0102] The experimental results are as Figure 4 shown: 1,2,3,4,6-Pentagalloylglucose significantly reduced the secretion levels of IL-1β ( Figure 4 A) and IL-6 ( Figure 4 B) in the mouse serum. Senescent cells can secrete a variety of factors to further promote the aging of the body, and senescence-associated secretory factors are important markers for evaluating the aging of the body. After the intervention of 1,2,3,4,6-pentagalloylglucose, the secretion levels of IL-1β and IL-6 in the mouse serum were significantly reduced. Combining the above experimental results, it can be known that 1,2,3,4,6-pentagalloylglucose can also delay aging in mice in vivo, which is consistent with the anti-aging effect of in vitro cell experiments.

[0103] Experimental Examples 16-18: Testing the NO level in the serum of aging mice

[0104] Experimental Examples 16-18 were respectively tested with the solutions prepared in Examples 5-7:

[0105] All the mice used in the experiment were 15-month-old aged mice, with 7 mice in each group. In Experimental Examples 16-18, the PGG composite solution in Examples 5-7 was intraperitoneally injected into the mice once every 4 days. After continuous administration for four weeks, blood was taken from the orbital cavity, serum was separated, and the secretion level of NO in the mouse serum was detected.

[0106] Control Example 5

[0107] The solution prepared in Comparative Example 2 was used for testing, and the testing method was the same as that in Experimental Example 16.

[0108] The experimental results are as Figure 5 shown: Compared with Control Example 4, the level of NO in the serum of aging mice was significantly increased after treatment with 1,2,3,4,6-pentagalloylglucose. This indicates that 1,2,3,4,6-pentagalloylglucose can effectively improve the vascular function in vivo.

[0109] The experiments and results of the present invention prove that 1,2,3,4,6-pentagalloylglucose can effectively inhibit the senescence of vascular endothelial cells and vascular aging.

[0110] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it; although the present invention has been described in detail with reference to the foregoing embodiments, those of ordinary skill in the art should understand that they can still modify the technical solutions described in the foregoing embodiments, or perform equivalent replacements on some or all of the technical features; and these modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. Use of 1,2,3,4,6-pentagalloylglucose in the preparation of a product for anti-vascular aging.

2. The application according to claim 1, wherein The effective substance concentration of 1,2,3,4,6-pentagalloylglucose for improving the senescence of vascular endothelial cells is 0.5 - 20 μM.

3. The application according to claim 1, wherein The effective substance concentration of 1,2,3,4,6-pentagalloylglucose for improving the senescence of vascular endothelial cells is 10 μM.

4. The application according to claim 1, wherein 1,2,3,4,6-pentagalloylglucose is used to improve the senescence of vascular endothelial cells, and the vascular endothelial cells include primary human umbilical vein endothelial cells.

5. An anti-vascular aging composition based on 1,2,3,4,6-pentagalloylglucose, characterized in that, Its components include 1,2,3,4,6-pentagalloylglucose and optional excipients.

6. The anti-aging blood vessel composition according to claim 5, characterized in that The anti-vascular aging composition comprises the following components by weight percentage: 0.01% - 0.5% of 1,2,3,4,6-pentagalloylglucose and the balance of excipients.

7. The anti-aging vascular composition according to claim 6, characterized in that The excipients include at least one of an antioxidant and an anti-inflammatory agent.

8. The anti-aging vascular composition according to claim 7, wherein, The antioxidant includes at least one of vitamin C and catechin; The anti-inflammatory agent includes tea polyphenols.

9. Use of the anti-vascular aging composition according to any one of claims 5 - 8 in the preparation of a food or a health product.

10. Use of the anti-vascular aging composition according to any one of claims 5 - 8 in the preparation of an anti-vascular aging drug.

Images